drugset / Trial / NCT01750086

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086

Phase 4 Completed 27 enrolled Massachusetts General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Timeline

Start
2013-01
Primary completion
2014-04
Completion
2014-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 70 mg Oral
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 40 ug Subcutaneous